Individualised axitinib dosing for patients with metastatic kidney cancer

In the following video interview with Practice Update, Dr Nancy Davis from Vanderbilt University Medical Center in Nashville, Tennessee, USA talks about a study looking at individualised dosing of axitinib for patients with metastatic renal cell carcinoma (RCC) based on toxicity.

This was a single-arm study in patients with metastatic predominately clear cell RCC who had already been treated with a checkpoint inhibitor, such as nivolumab. Patients started on the standard dose of axitinib (5 mg twice a day), and their dose was increased by 1 mg twice a day every 2 weeks, assuming they did not have any recurrent moderate adverse events (grade 2) or any severe, life-threatening or disabling adverse events (grade 3 or 4). In these situations, the dose of axitinib was decreased by 1 mg each time allowing for individualised dosing based on the tolerance of the patient to the medication.

The study shows that dose modification is feasible and patients still had a reasonable response to treatment and progression-free survival. The dose of axitinib can be individualised according to tolerability and not necessarily lose efficacy.

Watch the video interview on Practice Update here

Share this Post!

Related post